公司資料
INmune Bio 股價、新聞與催化劑
- 股票代碼:
- INMB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.13 USD (-1.84%)
收盤價
最後更新: 2026年8月17日
37.8M USD
市值
股價為何變動
As of Aug 17, 2026, INMB closed down 1.84% at $2.13. No new same-company headline was identified in the current news window.
公司概覽
Innate-Immune Therapeutics
INmune Bio develops therapies that modify innate immune responses. Its programs span cell therapy, neuroinflammation and cancer biology.
CORDStrom
CORDStrom is an allogeneic umbilical-cord-derived stromal-cell therapy being developed for recessive dystrophic epidermolysis bullosa, a severe inherited skin disorder.
XPro in Alzheimer's Disease
XPro1595 is a selective soluble-TNF inhibitor in clinical development for early Alzheimer's disease. The program is designed to suppress harmful neuroinflammation while preserving beneficial transmembrane-TNF signaling.
INB03 Oncology Program
INB03 applies the same soluble-TNF mechanism to cancer, with preclinical work evaluating whether it can overcome treatment resistance and reduce metastasis in HER2-positive disease.
INKmune
INKmune is a cell-based medicine designed to prime a patient's natural-killer cells into tumor-killing memory-like cells. It is being evaluated in an open-label Phase 1/2 prostate-cancer study.
未來催化劑
- UK marketing-authorization submission for CORDStrom around mid-summer 2026.
- European Medicines Agency filing for CORDStrom following the UK submission.
- FDA BLA submission for CORDStrom in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。